Both Johnson & Johnson as well as Pfizer could face new competition in the prostate cancer market.
News & Analysis: Bayer AG (ADR)
Despite getting approval in the U.S. and Canada, European counterparts weren't impressed by Vitraki.
Home Depot rose despite reporting mixed results, and Elanco announced a deal with Bayer for its animal health business.
See why these three stocks missed out on the broader market's rise on Tuesday.
The falling costs of genomic sequencing have led to exponential growth in synthetic biology. Ginkgo Bioworks' Chief Commercial Officer shares a few things investors should know about this fast-growing field.
Next-generation biotech products could threaten the existence of agricultural nutrient producers, but few seem to be taking notice.
Companies across the agricultural value chain are investing in digital tools to help farmers. Here are three to put on your radar.
A $289 million dollar verdict by a California jury could mean Bayer's on the hook for billions in damages tied to Roundup.
The company's pending acquisition faces an uncertain road to approval, which presents unique risks to investors.
Low commodity prices have led to a wave of consolidation in agricultural industries. This year could make or break $186 billion in deals.